Evolution of treatment for Hodgkin's disease: a population-based study of radiation therapy use and outcome

被引:9
作者
Hodgson, DC
Zhang-Salomons, J
Rothwell, D
Paszat, LF
Tsang, RW
Crump, M
Mackillop, WJ
机构
[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada
[3] Queens Univ, Radiat Oncol Res Unit, Kingston, ON, Canada
关键词
Hodgkin's disease; radiation therapy; mortality; survival rate;
D O I
10.1016/S0936-6555(02)00417-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To examine changes in radiotherapy (RT) use, cause-specific survival (CSS), and overall survival (OS) in a population-based cohort of Hodgkin's disease (HD) patients diagnosed from 1982 to 1996. Materials and Methods: Adult patients with HD diagnosed from 1 January 1982 to 31 December 1996 (n=3957) were identified from the Ontario Cancer Registry. The cohort was divided into three consecutive 5-year periods: 1982-1986, 1987-1991, and 1992-1996. RT use, CSS and OS in each of these three periods were compared. For the entire cohort, the cumulative incidence of different causes of death was calculated. Results: The proportion of patients receiving RT within 11 weeks of diagnosis declined over the three consecutive periods (25.1% 15.6%. 11.7%. P<0.001), as did the proportion receiving RT within 45 weeks (57.0%, 51.0%, 48.1%; P<0.001). There was a significant increase in 5-year CSS over time (81%, 87%, 89%; P<0.001), and OS (72%, 77%, 82%; P<0.001), which remained significant in multivariable analyses. The cumulative incidence of death from causes other than HD was equal to the incidence of HD-related death within 12 years of diagnosis. Conclusions: There was a significant decline in the use of RT as the primary treatment modality and as part of the initial management of HD from 1982-1996 in Ontario. A greater proportion of patients received their RT after a delay consistent with the receipt of prior chemotherapy. There was also a significant increase in the CSS and OS over this period. These findings are in keeping with the adoption of effective chemotherapy in the treatment of HD. (C) 2003 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 49 条
[1]   Hodgkin's disease in a national and hospital population: Trends over 20 years [J].
Abrahamsen, AF ;
Egeland, T ;
Hansen, S ;
Langholm, R ;
Holte, H ;
Kvaloy, S .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (14) :2380-2383
[2]   INCIDENCE OF 2ND CANCERS IN PATIENTS TREATED FOR HODGKINS-DISEASE [J].
BOIVIN, JF ;
HUTCHISON, GB ;
ZAUBER, AG ;
BERNSTEIN, L ;
DAVIS, FG ;
MICHEL, RP ;
ZANKE, B ;
TAN, CTC ;
FULLER, LM ;
MAUCH, P ;
ULTMANN, JE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (10) :732-741
[3]   Late effects of treatment for early stage Hodgkin's disease [J].
Brierley, JD ;
Rathmell, AJ ;
Gospodarowicz, MK ;
Sutcliffe, SB ;
Munro, A ;
Tsang, R ;
Pintilie, M .
BRITISH JOURNAL OF CANCER, 1998, 77 (08) :1300-1310
[4]   CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].
CANELLOS, GP ;
ANDERSON, JR ;
PROPERT, KJ ;
NISSEN, N ;
COOPER, MR ;
HENDERSON, ES ;
GREEN, MR ;
GOTTLIEB, A ;
PETERSON, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484
[5]  
CARDE H, 1988, NATL CANCER I MONOGR, P303
[6]   CLINICAL STAGE-I AND HODGKIN STAGE-II DISEASE - A SPECIFICALLY TAILORED THERAPY ACCORDING TO PROGNOSTIC FACTORS [J].
CARDE, P ;
BURGERS, JMV ;
HENRYAMAR, M ;
HAYAT, M ;
SIZOO, W ;
VANDERSCHUEREN, E ;
MONCONDUIT, M ;
NOORDIJK, EM ;
LUSTMANMARECHAL, J ;
TANGUY, A ;
DEPAUW, B ;
COSSET, JM ;
CATTAN, A ;
SCHNEIDER, M ;
THOMAS, J ;
MEERWALDT, JH ;
SOMERS, R ;
TUBIANA, M .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (02) :239-252
[7]   Variation in survival of adult patients with haematological malignancies in Europe since 1978 [J].
Carli, PM ;
Coebergh, JWW ;
Verdecchia, A .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2253-2263
[8]  
Clarke E A, 1991, IARC Sci Publ, P246
[9]  
DAVIS S, 1985, CANCER-AM CANCER SOC, V56, P1710, DOI 10.1002/1097-0142(19851001)56:7<1710::AID-CNCR2820560741>3.0.CO
[10]  
2-T